Celsion Corp. reported positive data from the phase 1b trial evaluating its GEN-1 treatment with neoadjuvant chemotherapy in patients with advanced ovarian cancer.
The study involved 14 patients who received the complete treatment and demonstrated 100% disease control rate and an 86% objective response rate. There was also a 100% objective response rate among the five patients who were treated with the highest dose.
Further, all the patients showed successful resections of tumors and experienced a significant reduction in their CA-125 protein levels.
Celsion intends to conduct another study evaluating GEN-1 in combination with Genentech USA Inc.'s Avastin as a second-line treatment. The company also plans to continue its clinical trials on newly diagnosed patient population.
Celsion stocks were up nearly 63% to $4.34 per share as of 11:14 a.m. ET on June 5.